Tackling Tissue Specificity: The Translational Journey from Antigen Selection to Clinical Proof-of-Concept

Time: 1:45 pm
day: Conference Day Two


  • Selecting the antigen of choice for delivery/presentation with MHCII
  • Highlighting data showing tissue specificity, bystander effect, disease modification, and persistence
  • Discussing plans for clinical proof-of-concept for direct measurement of endogenously expanded Treg cells